Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Oh on the Importance of Identifying DNA Damage Repair Mutations in Prostate Cancer

April 23rd 2020

William K. Oh, MD, discusses the importance of identifying DNA damage repair mutations in prostate cancer.

Real-World Analysis Supports Upfront Use of Radium-223 in mCRPC

April 22nd 2020

Rana R. McKay, MD, discusses the results of the real-world analysis with radium-223 and other exciting research in the mCRPC field.

Dr. Pettaway on the Prevalence of Germline Mutations in Diverse Populations With Prostate Cancer

April 22nd 2020

Curtis A. Pettaway, MD, professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses the prevalence of germline mutations in diverse populations with prostate cancer.

Dr. Polascik on Harmonizing Genetic Testing Guidelines in Prostate Cancer

April 22nd 2020

Thomas J. Polascik, MD, a urologic oncologist at Duke University, discusses efforts that are being made to harmonize genetic testing guidelines in prostate cancer.

FDA Approval Sought for Relugolix in Prostate Cancer

April 21st 2020

A New Drug Application has been submitted to the FDA for single-agent relugolix for use as a treatment for men with advanced prostate cancer.

Dr. Parker on the Rationale for the RADICALS-RT Trial in Prostate Cancer

April 20th 2020

Chris Parker, MD, discusses the rationale for the phase III RADICALS-RT trial in prostate cancer.

Dr. Tagawa on Ongoing Research With 225Ac-J591 in mCRPC

April 17th 2020

Scott T. Tagawa, MD, MS, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, and associate attending physician, Weill Cornell Medical Center/NewYork-Presbyterian Hospital, discusses ongoing research with 225Ac-J591 in metastatic castration-resistant prostate cancer.

Dr. Morris on OS Data With Apalutamide in Prostate Cancer

April 15th 2020

David Morris, MD, FACS, discusses overall survival data with apalutamide in prostate cancer.

Dr. Hwang on the Utility of Antiandrogens in Metastatic Prostate Cancer

April 14th 2020

Clara Hwang, MD, discusses the utility of antiandrogens in patients with metastatic prostate cancer.

High BMI, Weight Gain Tied to Increased Mortality in Prostate Cancer

April 13th 2020

Obese men with nonmetastatic prostate cancer have higher cardiovascular disease–related mortality and all-cause mortality, and potentially increased prostate cancer–specific mortality.

Early Intensification With Apalutamide Is Key in Metastatic Castration-Sensitive Prostate Cancer

April 13th 2020

Neeraj Agarwal, MD, discusses the implications of the PFS2 data from the TITAN trial in metastatic castration-sensitive prostate cancer.

PSMA-Targeted Radionuclide Therapy Shows Preliminary Activity in mCRPC

April 10th 2020

Scott T. Tagawa, MD, MS, discusses the results of the phase I dose-escalation trial, the advantages of using an alpha emitter and a monoclonal antibody, and the possibility of combining the modality with other classes of agents in prostate cancer.

Dr. Tagawa on Targeting PSMA in Prostate Cancer

April 10th 2020

Scott T. Tagawa, MD, MS, discusses the utility of beta and alpha emitters in targeting PSMA in prostate cancer.

Dr. Armstrong on the Utility of Pamiparib and Other PARP Inhibitors in Prostate Cancer

April 10th 2020

Andrew J. Armstrong, MD, discusses the utility of pamiparib and other PARP inhibitors in prostate cancer.

Dr. Antonarakis on Trial Examining Sipuleucel-T Plus Radium-223 in Bone-Metastatic CRPC

April 9th 2020

Emmanuel S. Antonarakis, MBBCh, discusses the design of a randomized phase II study of sipuleucel-T with or without radium-223 dichloride in men with asymptomatic bone-metastatic castrate-resistant prostate cancer.

Dr. Agarwal on PFS2 Data From the TITAN Trial in mCSPC

April 9th 2020

Neeraj Agarwal, MD, discusses data from a posthoc analysis of the phase III TITAN trial in patients with metastatic castration-sensitive prostate cancer.

Dr. McKay on the Utility of Radium-223 in the Treatment of mCRPC

April 9th 2020

Rana R. McKay, MD, discusses the utility of radium-223 in metastatic castration-resistant prostate cancer.

Dr. Beltran on the Utility of Liquid Biopsies Versus Tissue Biopsies in CRPC-NE

April 8th 2020

Himisha Beltran, MD, discusses the utility of liquid biopsies versus tissues biopsies in castration-resistant neuroendocrine prostate cancer.

Dr. Oh on the Role of Radiopharmaceuticals in mCRPC

April 8th 2020

William K. Oh, MD, discusses the role of radiopharmaceuticals in metastatic castration-resistant prostate cancer.

Dr. Grivas on Potential Combinations With Cabazitaxel in Prostate Cancer

April 7th 2020

Petros Grivas, MD, PhD, discusses potential combination regimens with cabazitaxel in prostate cancer.